Atara Biotherapeutics (United States)

Recent papers from Atara Biotherapeutics (United States)

1. Core Coefficient quantifies transcription-factor functional dominance for therapeutic target selection2026
2. Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling developmentFrontiers in Immunology · 2026
3. Nonclinical Safety Assessment of SBT777101, a CAR-Engineered Regulatory T Cell Therapy for Autoimmune DiseasesToxicological Sciences · 2026
4. In vivo genome editing of central nervous system SIV reservoirs in ART-suppressed rhesus macaquesMolecular Therapy — Nucleic Acids · 2026
5. Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell Lymphoma2026
6. Phase 2b Trial of a Na V 1.8 Inhibitor for Acute PainNew England Journal of Medicine · 2026
7. Fully Modified SpyCas9 Guide RNAs Enable Robust Genome Editing In Cells and In Vivo2026
8. Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness ConsortiumAmerican Journal of Clinical Dermatology · 2026
9. Inhibition of Cough-Causing Nociceptors by Selective NaV Channel BlockersPhysiology · 2026
10. Spatiotemporal dynamics of adoptively transferred stem-like CD8 ⁺ T cells in the tumor microenvironment following vaccination2026
11. First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian CarcinomaClinical Cancer Research · 2026
12. Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and EfficacyCPT Pharmacometrics & Systems Pharmacology · 2026
13. Multiplex gene editing suppresses random integration of hepatitis B virus DNA in chronically infected liverMolecular Therapy — Nucleic Acids · 2026
14. Abstract LB149: Progenitor-to-intermediate differentiation of exhausted CD8+T cells is enhanced by HPK1 inhibition during anti-PD-1 therapyCancer Research · 2026
15. Abstract 5592: QL535: A novel CD2-costimulating PSMA-targeted T-cell engager with dose-responsive efficacy in PDX models and a favorable GLP toxicology profile in NHPCancer Research · 2026
16. Abstract 2694: Dissecting the mechanisms of drug resistance development post neoadjuvant osimertinib treatment in EGFR-mutant non-small lung cancer.Cancer Research · 2026
17. Abstract 2242: Dual TTK/PLK1 inhibition combined with G-CSF treatment synergistically suppresses metastatic progression in triple-negative breast cancer.Cancer Research · 2026
18. Abstract 2644: Enhancing safety to unlock efficacy: A novel class of conditionally-activated T cell engagers for solid tumors.Cancer Research · 2026
19. Abstract 1261: Mutation-dependent sensitivity to the dual TTK/PLK1 inhibitor BAL0891 in patient-derived gastric cancer organoids.Cancer Research · 2026
20. Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )Pediatric Dermatology · 2026